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ABSTRACT The rise of antimicrobial resistance in uropathogens has complicated
the management of urinary tract infections (UTIs), particularly in patients who are af-
flicted by recurrent episodes of UTIs. Antimicrobial-resistant (AR) uropathogens per-
sistently colonizing individuals at asymptomatic time points have been implicated in
the pathophysiology of UTIs. The dynamics of uropathogen persistence following
the resolution of symptomatic disease are, however, mostly unclear. To further our
understanding, we determined longitudinal AR uropathogen carriage and clonal per-
sistence of uropathogenic Escherichia coli, Proteus mirabilis, and Klebsiella pneu-
moniae isolates in the intestinal and urinary tracts of patients affected by recurrent
and nonrecurrent UTIs. Clonal tracking of isolates in consecutively collected urine
and fecal specimens indicated repeated transmission of uropathogens between the
urinary tract and their intestinal reservoir. Our results further implicate three in-
dependent routes of recurrence of UTIs: (i) following an intestinal bloom of uro-
pathogenic bacteria and subsequent bladder colonization, (ii) reinfection of the
urinary tract from an external source, and (iii) bacterial persistence within the
urinary tract. Taken together, our observation of clonal persistence following
UTIs and uropathogen transmission between the intestinal and urinary tracts
warrants further investigations into the connection between the intestinal micro-
biome and recurrent UTIs.
IMPORTANCE The increasing antimicrobial resistance of uropathogens is challeng-
ing the continued efficacy of empiric antibiotic therapy for UTIs, which are among
the most frequent bacterial infections worldwide. It has been suggested that drug-
resistant uropathogens could persist in the intestine after the resolution of UTI and
cause recurrences following periurethral contamination. A better understanding of
the transmission dynamics between the intestinal and urinary tracts, combined with
phenotypic characterization of the uropathogen populations in both habitats, could
inform prudent therapies designed to overcome the rising resistance of uropatho-
gens. Here, we integrate genomic surveillance with clinical microbiology to show
that drug-resistant clones persist within and are readily transmitted between the in-
testinal and urinary tracts of patients affected by recurrent and nonrecurrent UTIs.
Thus, our results advocate for understanding persistent intestinal uropathogen colo-
nization as part of the pathophysiology of UTIs, particularly in patients affected by
recurrent episodes of symptomatic disease.
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Urinary tract infections (UTIs) are among the most common bacterial infections,occurring more frequently in women, half of whom will experience at least one
episode in their lifetime (1). UTIs result in estimated yearly costs of $3.5 billion and 10.5
million office visits in the United States alone (2). Besides gender, a history of UTIs,
sexual activity, diabetes, obesity, and genetically determined susceptibility are major
risks factors associated with UTIs (2, 3). A UTI is diagnosed when urinary symptoms
coincide with evidence of urinary tract inflammation and urine cultures are positive for
a known uropathogen above a defined threshold (commonly 105 CFU/ml) (4, 5). The
majority of UTIs are caused by uropathogenic Escherichia coli (UPEC) strains, which are
specifically adapted to colonize the urinary tract (6). Besides UPEC, strains of Klebsiella
pneumoniae, Staphylococcus saprophyticus, Enterococcus faecalis, and Proteus mirabilis
are frequent causes of UTIs (2, 7).
Approximately 25% of women suffering from UTIs experience at least one recur-
rence of symptomatic UTI (rUTI) within a window of 6 months following the initial
infection (8). The model for the majority of recurrences postulates that uropathogens
persist in an intestinal reservoir and recolonize the urinary tract following periurethral
contamination (1, 9). Supporting this hypothesis, previous studies have shown that the
strain of UPEC associated with symptomatic UTIs is commonly found in fecal specimens
collected from the same patient (10, 11). Besides intestinal persistence, quiescent
intracellular reservoirs (QIRs) established by UPEC strains in the bladder epithelium,
reinfection from external sources, and asymptomatic bacteriuria have been implicated
in the pathophysiology of rUTIs (12–16). The dynamics of bacterial persistence during
the succession of resolution of the UTI, asymptomatic latency, and the recurrence of
symptomatic infection, knowledge of which could be used to help assess the relative
importance of different routes of rUTIs and guide the development of novel interven-
tions, have not yet been established.
With appropriate treatment, uncomplicated UTIs are commonly considered a be-
nign condition with no long-term medical consequences (17). However, these infec-
tions can cause pain, reduce the life quality of afflicted individuals (18), and progress to
pyelonephritis or sepsis if the uropathogen ascends to the kidneys or enters the
bloodstream (2). Thus, antimicrobial therapy remains a mainstay of treatment.
The rise of antimicrobial resistance in major uropathogens has complicated the
standard treatment of UTIs (6, 19). Today, antimicrobial-resistant (AR) strains of bacteria
associated with UTIs are frequently resistant to the most commonly used drugs (6), and
plasmids carrying the genes for extended-spectrum -lactamases (ESBLs) have rapidly
spread within the Enterobacteriaceae family (2). Alarmingly, ESBL-producing UPEC
strains are now also occurring in patients with no discernible risk factors for the carriage
of antimicrobial-resistant organisms (AROs), such as exposure to health care facilities
(20). The continued efficacy of empirical antibiotic therapy is particularly complicated in
patients afflicted by chronic rUTIs, who frequently have a history of repeated antibiotic
exposure that can lead to increasing antimicrobial resistance in uropathogens. For
these patients, strategies that can guide prudent empirical treatment are urgently
needed. The prevailing clinical concept is to treat individuals with a history of rUTIs
based on the antibiotic susceptibility profiles of uropathogens isolated during prior
episodes. This concept, however, requires assessment of the uropathogen populations
colonizing patients for existing genomic heterogeneity, as this can impact population-
level functional profiles (21, 22).
Genetic variation within pathogen populations can result from cocolonizing bacte-
rial lineages or the genetic diversification of pathogens under the selective pressures
encountered within their environment (22). Importantly, intrapatient strain diversity
can increase the standing diversity of clinically relevant features like virulence (21, 23)
or antibiotic resistance (24, 25), potentially hampering treatments that are based on the
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patient’s medical history. To date, there is limited knowledge about the extant genetic
diversity within the antibiotic-resistant uropathogen populations colonizing individual
patients and clonal persistence following the conclusion of antimicrobial therapy.
In this study, we define the genetic relatedness of 109 AR isolates of the major
uropathogens E. coli, P. mirabilis, and K. pneumoniae isolated from urine and fecal
specimens that were collected longitudinally from 14 patients affected by rUTIs and
non-rUTIs at symptomatic and asymptomatic time points. We combined clonal tracking
with semiquantitative culturing of urine and stool specimens to provide a temporally
resolved characterization of the dynamics of bacterial clearance and persistence fol-
lowing UTIs. Our data highlight substantial interpatient differences in the pathophys-
iology of rUTIs caused by AR uropathogens and confirm reinfection from external
sources, urinary persistence, or relapse from the intestinal reservoir to be three different
routes for rUTIs.
RESULTS
Study cohort and microbiology. Fourteen patients (median age, 63 years; age
range, 37 to 88 years) with symptomatic UTIs caused by AR uropathogens were
enrolled in this study (Table 1). Of these, seven patients (50%) experienced up to two
episodes of rUTIs during a follow-up period of 180 days after the conclusion of
antimicrobial treatment (Table 1). Three different uropathogens were cultured from
urine samples obtained at the time of the UTI; E. coli was isolated from the urine of 12
patients (5 patients with non-rUTIs, 7 patients with rUTIs), Klebsiella pneumoniae was
identified in one case (one non-rUTI), and Proteus mirabilis was cultured from samples
from two patients (one with a non-rUTI, one with a rUTI; Table 1). Both P. mirabilis and
E. coli were cultured from diagnostic urine samples by the research lab for patient 10,
but only E. coli was recovered from the same urine specimen by the clinical microbi-
ology lab.












GEN MIN NIT SAM FEP CAZ ATM CRO CFZ AMP CIP SXT DOX
1 37 Ertapenem 1 405 E. coli R S S R R R R R R R R R I
2 66 Ciprofloxacin 1 12 E. coli S S S R S R S R R R S S R
3 42 Nitrofurantoin 1 551 K. pneumoniae S S S R S I I R R R R R R
4 62 Nitrofurantoin 1 131 E. coli S S S S — S S R R R R S R
2 — E. coli — — — — — — — — — — — — —
5 54 Nitrofurantoin 1 131 E. coli S S S S R R R R R R R S I
2 69 E. coli S — S — S S — S S R S S —
6 43 Nitrofurantoin 1 131 E. coli R S S R R I I R R R R S I
2 — E. coli — — — — — — — — — — — — —
8 72 Meropenem 1 131 E. coli S S S R R R R R R R R R R
9 88 Doxycycline 1 131 E. coli S S S I R R R R R R R R S
10c 66 Ertapenem 1 131 E. coli S S S R R R R R R R R R R
1 P. mirabilis R R R R I S S R R R R R R
13 62 Nitrofurantoin 1 131 E. coli S S S R R R R R R R R R R
2 131 E. coli S S S R R R R R R R R R R
3 131 E. coli S S S R R R R R R R R R R
14 67 Meropenem 1 P. mirabilis S R R S I S S R R R R R R
2 P. mirabilis S R R R I S S R R R R R R
15 64 Ciprofloxacin,
co-trimoxazole
1 131 E. coli S S S S S S S S I R R S S
16 74 Ciprofloxacin,
nitrofurantoin
1 131 E. coli S S S I R R R R R R R R S
2 — E. coli — — — — — — — — — — — — —
18 43 Cefalexin 1 131 E. coli R S S S S S S S I R R R R
2 131 E. coli R S S I S S S S R R R R R
aAbbreviations and symbols: GEN, gentamicin; MIN, minocycline; NIT, nitrofurantoin; SAM, ampicillin-sulbactam; FEP, cefepime; CAZ, ceftazidime; ATM, aztreonam; CRO,
ceftriaxone; CFZ, cefazolin; AMP, ampicillin; CIP, ciprofloxacin; SXT, trimethoprim-sulfamethoxazole; DOX, doxycycline; R, resistant, S, susceptible; I, intermediate; —,
missing data for isolates unavailable for analysis.
bAll patients were female.
cPatient 10 received a kidney transplant.
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Consistent with previous reports (2), E. coli was the dominant uropathogen associ-
ated with UTIs in our study (12/14 patients). In silico multilocus sequence typing (MLST)
and core genome alignment of all E. coli strains cultured from diagnostic urine
specimens (n  17) and a set of reference strains (n  46; see Text S1 in the supple-
mental material) showed that the isolated ESBL-producing E. coli strains belonged to
the B2 (82.4%, 14 of 17) or D (17.8%, 3 of 17) phylogroup (Fig. 1a) and were
predominantly sequence type 131 (ST131) (13/17 isolates) (Table 1). Maximum likeli-
hood trees (based on 2,074 core genes that shared at least 95% nucleotide identity)
supported the MLST/phylogroup data, as all isolates identified as phylogroup B2 or D
clustered with reference strains from their respective phylogroup (Fig. 1a). Additionally,
we found that the majority of AR E. coli isolates collected at the time of diagnosis (DxU)
of a recurrence (3/4) were closely related to the clone isolated during the initial episode
of UTI (same-strain rUTIs). In a single case (patient 5), the isolate associated with the
recurrence fell into a phylogroup (phylogroup D) different from that of the strain
associated with the initial episode of UTI (phylogroup B2).
WGS reveals that most patients are stably colonized by clonal uropathogen
populations. We performed whole-genome sequencing (WGS) on 95 E. coli isolates, 13
P. mirabilis isolates, and 1 K. pneumoniae isolate cultured from urine and stool speci-
mens at symptomatic and asymptomatic time points (Table S1). To characterize the
genetic relatedness of the dominant uropathogen, E. coli, we constructed a species-
specific core genome comprising the genes shared at 95% identity. Phylogenetic
reconstruction using all E. coli isolates indicated that the isolates clustered by patient
rather than by habitat (Fig. 1b). To assess the genetic diversity of the within-patient AR
uropathogen populations colonizing individual patients, we identified single nucleo-
tide polymorphism (SNP) distances by alignment of raw reads to the reference assem-
bly of an isolate collected from the same patient (see Materials and Methods). Gener-
ally, SNP distances between isolates collected from the same patient were small
(Fig. 1c), with the E. coli populations of 6/12 patients (patients 1, 2, 6, 13, 15, and 16)
having an average of less than 5 SNPs (Fig. 1d), indicating that individual patients are
frequently colonized by a clonal population of AR uropathogens. Isolates clonal with
the DxU isolate (SNP distance  0) were recovered from stool samples from patients 1,
2, and 16 at asymptomatic time points, highlighting that AR uropathogens can stably
colonize patients. Moreover, the recovery of clonal isolates from urine and stool
samples at asymptomatic time points from multiple patients (patients 6, 8, and 18;
Fig. S1) highlights the interconnectedness of the uropathogen populations colonizing
the urinary and intestinal tracts. In three of the four patients (patient 13, 14, and 18)
with available diagnostic isolates from a recurrence of symptomatic UTI, we found that
each episode was associated with the same lineage (10 SNPs).
Notably, E. coli isolates collected from three patients (patient 5, 9, and 10) exhibited
substantially more mutations (50 SNPs; Fig. 1d). While the isolation of clones from two
different phylogroups during subsequent episodes explained the high SNP distance for
patient 5, the E. coli populations of patients 9 and 10 showed a substantially elevated
number of mutations between isolates belonging to the same phylogroup (average
SNP distances, 162.16 and 50.66, respectively). Analysis of the SNP identity for the E. coli
populations of patients 9 and 10 showed no substantial change in the transition/
transversion rate or the nature of the base substitutions (Fig. S2), both of which are
frequently associated with hypermutating lineages, compared to the E. coli communi-
ties collected from all other patients.
Distinct patterns of uropathogen persistence are associated with rUTI. To
determine the temporal dynamics of pathogen colonization, we performed semiquan-
titative culture of stool and urine specimens. The results indicated a trend toward lower
AR uropathogen burdens at the asymptomatic time point for patients that did not
experience a rUTI during the duration of study enrollment (Fig. 2). Thus, all cultures of
post-antimicrobial treatment (pAT) urine and stool specimens were negative for AR
uropathogens for 4/7 (57.1%) and 2/7 (28.6%) of all non-rUTI patients, respectively.
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FIG 1 The clonal diversity of the uropathogen population varies between individual patients. (a) UTI-associated E. coli strains
belong to the major phylogroups D and B2. The maximum likelihood phylogenetic tree includes all available E. coli isolates
(Continued on next page)
Comparative Genomics of Drug-Resistant Uropathogens ®
July/August 2019 Volume 10 Issue 4 e01977-19 mbio.asm.org 5
 on S
eptem











However, we cultured isolates from the same lineage as the isolate cultured from the
diagnostic urine specimen for the majority of non-rUTI patients (71.43%, 5 of 7; Fig. 1d
and Fig. S1) at asymptomatic time points, indicating that AR uropathogen colonization
alone does not explain all rUTIs.
Integrating information on isolate clonality with the results of semiquantitative
culturing revealed three distinct temporal patterns of bacterial clearance and persis-
tence associated with recurrences. First, in patients 4 and 6 (both of whom were
colonized with E. coli), recurrence was associated with high urine uropathogen titers
that persisted following the conclusion of antimicrobial therapy (Fig. 2). Interestingly,
both patients were persistently colonized by isolates from a single lineage, indicating
that the causative agent of the urinary tract infection resisted clearance by antibiotic
therapy, persisted in the urinary tract, and later caused a recurrence of symptomatic
disease.
Second, we observed that recurrences were preceded by several negative pAT urine
and stool cultures in patient 5 (who was colonized with E. coli). As the isolate associated
with the recurrence fell into a different phylogroup, reinfection from an external source
may have been the cause for the rUTI in this patient.
Finally, four cases of rUTI associated with either E. coli (patients 13, 16, and 18) or P.
mirabilis (patient 14) showed complex patterns of interspersed negative and positive
urine specimens following the conclusion of antimicrobial therapy (Fig. 2). In all four
patients, we observed that increased AR uropathogen abundance in fecal specimens
preceded positive urine cultures associated with isolates from the same lineage (Fig. 2;
Fig. S1 and S3). Moreover, we frequently observed a bloom, defined as a substantially
FIG 1 Legend (Continued)
cultured from diagnostic urine samples and publicly available reference strains. Diagnostic isolates are depicted in red; publicly
available reference genomes are indicated in black. Escherichia marmotae strain HT073016 was added as an outgroup (italics). (b)
Phylogenetic reconstruction indicates that the E. coli isolates clustered by patient. The maximum likelihood phylogenetic tree
includes all available E. coli isolates cultured from urine and stool samples. Isolates are colored according to patient. E. coli strain
UTI89 was added as a reference. (c) Isolates from the same patient generally differed by 50 SNPs. The histogram shows the
number of SNPs identified for all within-patient pairwise comparisons of E. coli isolates. (d) The average number of SNPs identified
in all pairwise comparisons of E. coli isolates collected from each patient. Error bars depict standard deviations.
FIG 2 Recurrent urinary tract infections are associated with differences in stool and urine uropathogen density. (Top) Non-rUTI patients; (bottom) patients with
rUTIs. Subsequent episodes for rUTI patients are depicted from bottom to top in the bottom panel. Different colonization patterns are indicated by header
background colors: red, persistent urinary tract colonization; turquoise, nonpersistent colonization; blue, intestinal blooms. Patient identifiers are given on the
top of each panel. The bubble size corresponds to the number of CFU that grew on species-specific selective agar plates (see Materials and Methods). Yellow
bubbles correspond to the culture results for urine samples; brown bubbles correspond to the culture results for stool samples. Missing culture data are
indicated by gray fields. A red line indicates the time frame in which an rUTI patient experienced a recurrence.
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increased ARO abundance relative to that in the previously collected fecal specimen,
associated with the fecal specimen collected at a time point preceding or coinciding
with the time of detection of the same lineage in urine (e.g., patient 13, episode 2,
0 days pAT; patient 14, episode 1, 7 days pAT; patient 18, episode 1, 0 days pAT).
Importantly, episodes of rUTI following such a bloom were caused by the lineage of AR
E. coli that we previously isolated during the intestinal bloom in three patients (patients
13, 14, and 18; Fig. 2; Fig. S1 and S3). However, not every bloom was immediately
followed by an episode of rUTI (patient 8; Fig. 2) or persistent colonization of the urinary
tract (e.g., patient 15, 0 to 7 days pAT), implicating additional factors in the onset of
rUTIs.
16S rRNA gene sequencing of the urinary microbiota supported the patterns of
bacterial persistence in urine following the conclusion of antimicrobial therapy identi-
fied using semiquantitative culturing (Fig. S4a; Data Set S1). We observed consistently
high relative abundances of Enterobacteriaceae for patients 4 and 6, while increased
relative abundances in urine (e.g., patient 10 at 30 days pAT, patient 13 at 30 days pAT)
coincided with the increased abundances measured by semiquantitative culturing.
Overall, 16S rRNA sequencing results showed a high concordance with culture-based
identification of AR uropathogens (Fig. S4d), highlighting that the pathogenic agent
was correctly identified by diagnostic urine culturing. We did not identify the specific
microbiota compositions at asymptomatic time points with an insignificant uropatho-
gen load (see Materials and Methods) that differentiated patients with rUTIs and those
with non-rUTIs (Fig. S4b). Similarly, we did not observe a significant difference between
the urinary microbiota composition at matched time points preceding a recurrence
(Fig. S4c). This suggests that no specific microbiota signature of asymptomatic urine
was associated with recurrence or protection against recurrence in the analyzed set of
patients.
Uropathogens show high levels of resistance to a spectrum of antibiotics used
to treat UTIs. We observed high levels of phenotypic resistance against antibiotics
commonly used to treat UTIs in all isolates longitudinally collected from the intestinal
and urinary tracts (Fig. 3; Data Set S1). Isolates were frequently resistant to ciprofloxacin
(97.2%), doxycycline (54.6%), gentamicin (29.6%), trimethoprim-sulfamethoxazole
(70.4%), aztreonam (48.1%), cephalosporins (ceftriaxone, 80.6%; cefazolin, 83.3%; cef-
tazidime, 42.6%; cefepime, 45.4%), and ampicillin-sulbactam (50%). However, we ob-
served no resistance against meropenem, and non-P. mirabilis isolates were only
sparsely resistant to nitrofurantoin (5.3%). We did observe a high similarity of the
susceptibility profiles of E. coli and P. mirabilis strains cultured from different body
habitats or at different time points from the same patient (Fig. 3). Most notably, all 27
isolates cultured from stool and urine specimens from patient 13 during and after three
subsequent episodes of symptomatic UTI had similar resistance patterns. The suscep-
tibility profiles of the E. coli isolates from patients 4, 8, and 9 were markedly more
FIG 3 Isolate antibiotic susceptibility profile clusters by patient. A heat map of the results of antibiotic susceptibility testing of all isolates is shown. Profiles
of susceptibility to specific antibiotics and individual isolates are hierarchically clustered on the y axis and the x axis, respectively. Black squares, resistance; dark
gray squares, intermediate phenotype; white squares, susceptibility; light gray squares, missing data. The patient and episode of isolation, and the isolate
species identity are given as colored annotations on top of the heat map.
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variable. This variability was not correlated with the isolate source, indicating that
specific within-clone genetic differences might contribute to the observed difference in
their susceptibility profiles.
Querying the isolate whole-genome sequences for acquired antibiotic resistance
genes (ARGs) using the RGI software and the ResFinder database, we identified key
differences for the isolates cultured from patients 8 and 9 that explained most of the
observed phenotypic variation (Fig. 3 and 4; Data Set S1). We identified the absence of
tetA, mediating resistance against tetracyclines, as a potential reason for the increased
susceptibility of the DxU isolate of patient 9 (9-E1-DxU) to doxycycline. Also, we
identified the blaCTX-M-98 -lactamase solely in the DxU isolate of patient 8 (8-E1-DxU)
that was resistant to all tested cephalosporins, while isolates from all asymptomatic
time points harbored blaCTX-M-27 and were susceptible to cefepime and ceftazidime.
These observed differences, as well as the observation that the genomes of individual
isolates (isolates 8-E1-U11 and 9-E1-DxU) encoded fewer ARGs than all other isolates
from the same patient, indicate that the absence of specific mobile genetic elements or
plasmids might cause an altered resistance profile of individual isolates.
As expected, all but 22 isolates (87/109, 79.8%) harbored ESBL-encoding genes
(Fig. 4). Of these, the globally most widely distributed ESBL, blaCTX-M-15 (50/109), was
most frequently identified. Additionally, -lactamase genes blaOXA-1 (48/109) and
blaTEM-1 (39/109) were frequently identified in the isolates, and blaOXA-1 was commonly
present in isolate genomes with blaCTX-M-15 (36/50). These isolates exhibited increased
resistance against third- and fourth-generation cephalosporins, like cefepime and
ceftazidime, highlighting the rise of resistance against later-generation -lactams
(Fig. 3). Moreover, emerging mutations in the parC and the gyrA genes, associated with
broad-spectrum resistance against fluoroquinolones, were virtually omnipresent in E.
coli isolates (93/95). Overall, the P. mirabilis isolates harbored the most diverse resis-
tance gene repertoire, including as many as 26 unique ARGs, which frequently included
genes for multiple ESBLs.
FIG 4 Isolate antibiotic gene repertoire clusters by patient. A heat map of all resistance genes identified by use of the RGI software and the ResFinder database
in the genomes of all isolates is shown. Resistance genes and individual isolates are hierarchically clustered on the y axis and x axis, respectively. Black squares,
the presence of a specific resistance gene. The patient and episode of isolation, and the isolate species identity are given as colored annotations on top of the
heat map.
Thänert et al. ®
July/August 2019 Volume 10 Issue 4 e01977-19 mbio.asm.org 8
 on S
eptem











Within-patient uropathogen populations share resistance plasmids and viru-
lence genes. Integrating three tools used to identify plasmidic elements (the Plasmid-
Finder, Recycler, and PlasmidSpades software) with in silico ARG typing (see Materials
and Methods), we observed that the fraction of mobilized ARGs was similar for the
majority of E. coli isolates cultured from the same patient irrespective of their source
(Fig. S5). While point mutations that mediate resistance against fluoroquinolones,
fosfomycin, and peptide antibiotics were exclusively typed to chromosomal locations,
the majority of ARGs were identified to be located on plasmidic elements (Fig. S5).
Genes for resistance to aminoglycosides, macrolides, sulfonamides, and trimethoprim
were exclusively identified on putative plasmid contigs (Fig. S5). To determine whether
the within-patient AR E. coli community shared a pool of common resistance plasmids,
we determined average nucleotide identity and coverage for each pairwise alignment
of all identified resistance plasmids from all isolates (see Materials and Methods and
Data Set S1). Hierarchical clustering of pairwise similarity indicated highly similar
resistance plasmid pools for isolates cultured from the same patient (Fig. S6), with the
exception of single isolates collected from patients 8 and 9. In silico ARG typing showed
that these plasmidic elements harbored the same resistance genes (Fig. S6). These
observations indicate that a defined pool of resistance plasmids shared by the majority
of AR E. coli clones colonizing the intestinal and urinary tracts of an individual
determines their susceptibility profile, which is similarly shared population wide.
Hierarchical clustering based on average nucleotide identity (Fig. S6) indicated that
one isolate cultured from each of patients 8 (isolate 8-E1-U11) and 9 (isolate 9-E1-DxU)
exhibited a significant change in the pool of resistance plasmids from that in all other
isolates collected from the same patient. Notably, the pool of ARGs typed to putative
plasmidic elements varied substantially for these isolates, with isolate 9-E1-DxU missing
the genes aph(3)-Ib and aph(6)-Id and isolate 8-E1-E11 solely retaining blaCTX-M-27
(Fig. S6). These observations indicate that plasmid replacement occurred in the uro-
pathogenic E. coli lineages cultured from patients 8 and 9, resulting in altered clinical
resistance profiles (Fig. 3; Fig. S6).
In silico characterization of the virulence profile of E. coli isolates showed that
isolates cultured from the same patients clustered together, indicating that all isolates
from the same lineage share the same putative urovirulence factors (PUFs) (Fig. S7; Data
Set S1). Genes encoding key virulence factors, like the fimbrial adhesin FimH (100% of
isolates), iron acquisition factors (Iha, 97.8%; FyuA, 100%; Irp2, 100%; ChuA, 100%; FeoB,
100%), or the bacteriocin Usp (93.7%), were virtually omnipresent among the drug-
resistant E. coli isolates. No virulence factors were restricted to or significantly associ-
ated with isolates cultured from rUTI patients. Similarly, isolates cultured from rUTI
patients did not harbor more total virulence factors than non-rUTI isolates, indicating
that no set of specific virulence factors was associated with rUTIs.
DISCUSSION
The rise of antibiotic resistance in uropathogens has complicated the effective
treatment of UTIs (6, 10). The rate-limiting side effects of antimicrobials as well as
limited strategies to identify patients at risk of a recurrence increase the mortality and
morbidity associated with UTIs caused by AROs (26). Previous studies have identified
the intestinal tract as a reservoir for uropathogens (11, 27), highlighting the relevance
of intestinal AR pathogen colonization for the pathology of UTIs. However, there is a
lack of prospective studies determining the transmission dynamics of drug-resistant
uropathogens between their intestinal reservoir and the urinary tract within individual
patients. Importantly, AR uropathogens might have unique patterns of recurrence
compared to their susceptible counterparts, as AR organisms have been shown to be
enriched following antibiotic interventions that cause the disruption of nonresistant
members of the microbiome. Studies focused on AR uropathogens are essential, as they
(i) have the potential of informing therapy that aims to limit the selection for drug
resistance by inappropriate treatment of AR UTIs, (ii) can identify patients at risk of a
recurrence, and (iii) guide the development of novel approaches preventing chronic,
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difficult-to-treat UTIs. Here, we combined temporally resolved semiquantitative culture
of stool and urine samples with genomic interrogation of the corresponding drug-
resistant isolates to characterize the patterns of uropathogen persistence and charac-
terize the uropathogen populations in rUTI and non-rUTI patients genotypically and
phenotypically.
In this study, we predominantly recovered isolates of the same sequence type (ST)
from stool and urine samples from each patient (11/12 patients). In a single patient,
patient 5, we observed that consecutive episodes of UTI were associated with E. coli
isolates from different phylogroups (ST131 phylogroup B2, ST69 phylogroup D). This
trend observed for within-patient sequence type homogeneity contradicts the findings
of previous studies that have shown substantial within-patient sequence type variabil-
ity of fecal ESBL-producing E. coli colonization or UPEC populations (11, 28, 29). As these
studies mostly utilized sampling schemes similar to the one applied in this study (11,
29), our observation of a single dominant sequence type per patient might be unique
for the pathophysiology of UTIs caused by AROs. The dominance of ST131, which is
frequently identified to be the predominant sequence type in cross-sectional studies of
drug-resistant infections (20) and was identified for 76.5% (13/17) of isolates collected
during symptomatic infections in this study, as well as the lack of a dominant sequence
type associated with more susceptible isolates causing UTIs, might explain why our
observations deviate from the results of prior studies. While the structure and dynamics
of intestinal uropathogen populations have been extensively studied (15, 27, 30), less
is known about the population structure of intestinal AROs with uropathogenic poten-
tial. Characterization of pairwise SNP distances between isolates collected during UTI as
well as at asymptomatic time points revealed interpatient differences in the clonal
diversity of the AR Enterobacteriaceae populations in the intestine and the urinary tract
(Fig. 1B; see also Fig. S1 in the supplemental material). Thus, while the uropathogen
populations of most patients (10/14, patients 1, 2, 4, 6, 8, 13, 14, 15, 16, and 18)
comprised isolates of a single lineage separated by an average SNP distance of 15, the
E. coli populations of patients 9 and 10 were markedly more diverse (average SNP
distance, 50). Interpatient differences in the clonal diversity of intestinal ARO popu-
lations have previously been reported (10, 29) and could indicate that while a single
acquisition event may result in intestinal ARO colonization in the majority of patients,
individual patients may be predisposed to de novo acquisitions of resistant organisms
or colonized by hypermutating strains. While a change in the rate of transition/
transversion, often associated with hypermutating lineages of E. coli (31), was not
observed for the isolates collected from patients 9 and 10, the predominance of base
transitions over transversions observed here is consistent with the patterns observed in
hypermutating lineages with a defective methyl-directed mismatch repair system (32).
Moreover, UTIs are known to be associated with higher frequencies of hypermutators
(33), making this the most likely explanation for the higher SNP distance observed for
patients 9 and 10. Similar to previous results (34), we observed that the degree of
isolate core genome relatedness was explained by the host and not by the habitat,
indicating the lack of substantial genomic signatures associated with adaptation spe-
cifically to either the intestinal tract or the urinary tract. This is further supported by
previous studies highlighting that some of the same virulence factors that mediate
urinary tract colonization also increase the intestinal persistence of uropathogens (35,
36). Moreover, we found that specific clones of E. coli and P. mirabilis were isolated from
urine as well as stool samples, highlighting that these uropathogens are well adapted
to both habitats and suggesting continuous or intermittent transmission between
these ARO niches.
Historically, identification and genomic comparison of strains associated with rUTIs
to previous isolates from the same patient have been used to gain insights into the
mode of recurrence (37). A multitude of studies have reported variable proportions of
rUTIs that are associated with the clone from the first episode (same-strain rUTIs) and
different-strain rUTIs (10, 11, 27, 37). Our approach of combining serial semiquantitative
stool and urine culture with genomic characterization of the associated isolates allowed
Thänert et al. ®
July/August 2019 Volume 10 Issue 4 e01977-19 mbio.asm.org 10
 on S
eptem











us to overcome the limitations associated with the lack of longitudinal sample collec-
tion and gain unique, temporally resolved insights into the patterns of uropathogen
persistence following UTIs. We observed only a single case of a different-strain rUTI
(patient 5; Fig. 1). Interestingly, all stool samples cultured from this patient were
negative for AR Enterobacteriaceae, indicating that introduction from an extraintestinal
source might have caused the recurrence in this patient.
Several reports in mice and humans have implicated persistent bacteriuria as an
outcome of UTIs (1, 38–40). However, it remains controversial whether asymptomatic
bacteriuria predisposes patients to rUTIs, and different reports have either supported
(14) or refuted (15, 41) this assumption. Here, we observed persistently high urine titers
of AR E. coli (1  105 CFU/ml) in two patients (patients 4 and 6) that subsequently
experienced an episode of rUTI within 180 days after the conclusion of antimicrobial
therapy. Interestingly, the intestinal and urinary tracts of both patients were colonized
by a single lineage of E. coli. As the SNP distance between the urine isolates was low
(15 SNPs) and no other lineage of AR E. coli was isolated at any time point preceding
the recurrence, our observation implicates asymptomatic bacteriuria in the persistence
of AR uropathogens following UTIs. 16S rRNA sequencing confirmed the persistent
uropathogen dominance in the urinary microbiomes of these two patients. Recently, it
has been proposed that asymptomatic bacteriuria might represent a state of dysbiosis
on a spectrum of urinary microbiome health that prevents the restoration of bladder
homeostasis (42). This new paradigm and studies of host-pathogen interactions fol-
lowing infectious episodes (43) might help provide an understanding of how infections
can be followed by a phase of resilience to symptomatic disease, even though the
uropathogen is never cleared from the urinary tract and might cause subsequent
episodes of rUTIs.
With the observation that isolates genetically identical to UTI-associated E. coli
isolates could be found in the intestine (11, 27), periurethral contamination prior to
urethral introduction has become generally accepted as a mechanism of uropathogen
entry prior to UTIs. Here, we show that the uropathogen populations in the intestinal
reservoir and urinary tract are highly interconnected. In four patients (patients 6, 13, 14,
and 18) afflicted by rUTIs and one patient that experienced only a single episode of UTI
(patient 8), we isolated the same clone (SNP distance  0) from urine as well as from
stool samples (Fig. S1). Moreover, in four patients that later experienced rUTIs (patient
13, 14, 16, and 18), recurrences were preceded by at least one sterile urine sample.
However, we still isolated from fecal samples AR uropathogens at the time of culture-
negative urine collection, and the lineage associated with the recurrence was isolated
from stool samples prior to the recurrence. This supports the hypothesis that the
intestine is a reservoir for uropathogen persistence during antimicrobial therapy (11,
27). Moreover, we show that AR uropathogens resurface in the urinary tract following
or coinciding with the occurrence of increased stool titers (Fig. 2). Strikingly, we isolated
the same lineage that was associated with recurrences during these intestinal blooms
(Fig. 2; Fig. S1 and S3), suggesting that a highly dynamic process of urine clearance,
intestinal persistence, and urinary tract reinoculation fuels a cycle of rUTI in some
patients. The detection of a similar bloom in a non-rUTI patient (patient 8), however,
suggests that intestinal ARO blooms are not invariably succeeded by recurrences.
Consistently, prior studies have implied that the interplay of uropathogen and host
factors might result in a patient-specific rUTI pathophysiology (39, 44). The observation
of repeated AR uropathogen entry into the urinary tract without subsequent persistent
urinary tract colonization (patients 8, 9, 10, and 16; Fig. 2) suggests that the patho-
physiology of UTIs involves an iterative process of periurethral contamination, urinary
tract colonization, and bacterial clearance (Fig. 2). This observation necessitates an
understanding of intestinal AR uropathogen colonization as part of the pathophysiol-
ogy of rUTIs and advocates for intestinal ARO decolonization as part of routine UTI
treatment.
We observed that the majority of cultured AR uropathogens were resistant to
trimethoprim-sulfamethoxazole, which are commonly recommended as first-line drugs
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for UTIs (45). However, we observed resistance against nitrofurantoin only sparsely,
indicating that this drug remains an effective first-line option to treat UTIs caused by
uropathogenic E. coli strains. The continued efficacy of first-line drugs is critical to
maintain the clinical ability to control UTIs caused by AROs, as we commonly observed
resistance to important second-line drugs, like ciprofloxacin, levofloxacin, or third- and
fourth-generation cephalosporins. Similar trends have been reported in other studies of
AR E. coli and P. mirabilis strains worldwide (46–49), highlighting the need for novel
treatment options for UTIs in case residual drugs become ineffective. Such novel
strategies to treat and prevent UTIs, including vaccination (65), selective depletion of
uropathogens from their reservoirs (50), or antivirulence therapies (51), have already
been successfully tested in animal models.
While our approach of serially sampling the within-host ARO population in the
intestine and the urinary tract allowed us to describe their clonal diversity, the lack of
multiple isolates cultured from the same sample limited our ability to describe sub-
species ARO population dynamics and probably led to an underestimation of the
genetic diversity of the uropathogen populations. Moreover, analysis of multiple clones
per sample would enable in-depth analysis of within-host evolution, which has been
implicated to be important in the pathophysiology of other infectious diseases. Another
limitation of the exploratory study presented here is the small sample size, necessitat-
ing validation of our observations in a study with a large cohort of UTI patients. While
the findings obtained with the small subset warrant further validation, our observations
have a substantial potential for guiding future research avenues. Thus, based on our
results, evaluation of the connection of the intestinal microbiome and the pathophys-
iology of UTIs is a critical next step, as it can provide further insights into the gut-urinary
tract axis and help develop novel treatment strategies targeted to deplete the intestinal
uropathogen reservoir. In this context, future studies should also evaluate potential
differences in the pathophysiology of rUTIs between patients affected by pyelonephri-
tis and patients affected by cystitis, which was beyond the scope of this work.
Additionally, the focus of our study on AR uropathogens prevents the direct extrapo-
lation of our findings to the pathophysiology of UTIs caused by susceptible uropatho-
gens, specifically, fluoroquinolone-susceptible organisms. However, as the majority of
UTIs are now associated with resistant pathogens (specifically, fluroquinolone-resistant
pathogens) in a number of countries (52, 53), our observations are relevant to a
substantial subset of UTIs.
Taken together, by combining semiquantitative culturing with the comparative
genomics of serially sampled isolates, we provide support for substantial interpatient
differences in the pathophysiology of rUTIs caused by AR uropathogens. We demon-
strate that reinfection from external sources, urinary persistence, and intestinal persis-
tence are three routes for rUTIs. Moreover, we provide evidence for the repeated
transmission of uropathogens between the intestinal reservoir and the urinary tract and
evidence that rUTIs are frequently preceded by an intestinal bloom of uropathogens.
The data provided in this study expand our understanding of the temporal dynamics
of pathogen clearance and persistence following symptomatic infection and highlight
the importance of understanding intestinal ARO colonization as part of the pathophys-
iology of rUTIs. Thus, monitoring of intestinal AR uropathogen colonization could
inform the development of novel treatment strategies targeting intestinal decoloniza-
tion in patients with a history of AR rUTIs.
MATERIALS AND METHODS
Study design, study cohort, and sample collection. This prospective cohort study was conducted
to determine the patterns of uropathogen persistence in the intestinal and urinary tracts following UTIs
and to determine the genetic diversity, resistance, and virulence profiles of antimicrobial-resistant
uropathogen populations in both body habitats. The study was approved by the Washington University
Human Research Protection Office. Subjects were recruited from among patients at Barnes-Jewish
Hospital (BJH), St. Louis, MO, with positive urine culture results from standard-of-care testing. Patients
with a symptomatic UTI and with a urine culture positive for an ESBL-producing or fluoroquinolone-
resistant Enterobacteriaceae isolate that were diagnosed and treated by a clinician were included in this
study. Patients were excluded if they met one of the following conditions: they were 18 years of age;
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they had 1 organism at a level above the significance threshold detected in urine by the clinical
laboratory, recurrent Clostridioides difficile infection, intra-abdominal devices present, neutropenia (ab-
solute neutrophil count, 500 mm3), or intestinal mucosal disruption; they were unlikely to survive for
6 months or were pregnant or unwilling/unable to use contraception; they had short gut syndrome; they
used intestinal motility medication; they had inflammatory bowel disease, recent abdominal surgery,
active typhlitis or diverticulitis, current gastrointestinal graft-versus-host disease, human immunodefi-
ciency virus infection without antiretroviral therapy, or a CD4 count of 200 mm3; they were undergoing
peritoneal dialysis; or they had cirrhosis with ascites, active intra-abdominal malignancy, percutaneous
nephrostomy tubes, a chronic indwelling Foley or suprapubic catheter, chronic ileal conduit, active
hepatitis B or C, ureteral stent, or an active kidney stone. Patients with solid organ transplants were
included in the study. Subjects submitted stool and urine specimens to the study team at enrollment; the
end of UTI antimicrobial treatment; and days 3, 7, 14, and 30 posttreatment. Samples were kept on ice
during transport and immediately processed upon arrival to the lab. Written, informed consent was
obtained from all patients.
Culturing protocols. (i) Stool culturing. Stool samples (1 g each) collected at enrollment and on
days 0, 7, 30, and 180 post-antimicrobial treatment (pAT) were supplemented with an equal amount
(wt/vol) of phosphate-buffered saline (PBS) and vortexed to homogenize the samples. Ten 10-fold serial
dilutions were prepared in PBS, and 10 l of each of the first 10 dilutions was streaked onto selective agar
(Hardy Diagnostics, Santa Maria, CA, USA) specific to each patient’s identified ARO using a 10-l
calibrated loop. MacConkey (MAC) agar supplemented with ciprofloxacin (10 g/ml) was used for
ciprofloxacin-resistant Enterobacteriaceae, while ESBL-producing Enterobacteriaceae were cultured on
Hardy Diagnostics ESBL agar and MAC agar supplemented with cefotaxime (1 g/ml). The CFU were
enumerated following overnight incubation at 35°C. The identity of the cultured pathogens was
confirmed using matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-
TOF MS) (Vitek MS; bioMérieux, Durham, NC, USA). Single colonies were diluted in tryptic soy broth
(TSB)-glycerol and stored at 80°C for later analysis.
(ii) Urine culturing. Available urine specimens collected at diagnosis, enrollment, and days 0, 7, 30,
and 180 pAT were directly plated onto MacConkey agar (Hardy Diagnostics, Santa Maria, CA, USA) using
a 10-l calibrated loop to assess bacterial abundance semiquantitatively. The plates were incubated for
20 to 30 h at 35°C. The numbers of CFU were recorded as 10,000 CFU/ml, 10,000 CFU/ml, or 100,000
CFU/ml. The identity of the cultured pathogens was confirmed using MALDI-TOF MS (Vitek MS; bioMéri-
eux, France). Single colonies were diluted in TSB-glycerol and stored at 80°C for later analysis.
WGS. For whole-genome sequencing (WGS), a single isolate was chosen from each stool or urine
culture positive for each uropathogen. Isolates stored at 80°C were streaked onto a blood agar plate
(Hardy Diagnostics, Santa Maria, CA, USA) and incubated at 35°C overnight. The plates were scraped
using a sterile cotton swab, and the scraped material was resuspended in deionized water. Total DNA was
extracted from isolates using a QIAamp bacteremia DNA kit (Qiagen, Germantown, MD, USA). Genomic
DNA (0.5 ng) was used as the input for Illumina sequencing library preparation using a Nextera kit
(Illumina, San Diego, CA, USA) (54). The libraries were pooled at an equal concentration and sequenced
to a depth of 2.5 million reads (2  150 bp) on a NextSeq 500 HighOutput platform (Illumina, San
Diego, CA, USA). The remaining adapters were removed from demultiplexed reads using the Trimmo-
matic (v36) trimming tool (55) (parameters, leading, 10; trailing, 10; sliding window, 4:15; minlen, 60), and
potential human read contamination was removed using the DeconSeq (v4.3) tool (56) (default param-
eters). Draft genomes were de novo assembled from preprocessed reads using the SPAdes (v3.11.0)
algorithm (57) (parameters, -k 21,33,55,77 – careful). The resulting scaffolds.fasta files were used for all
downstream analyses. The quality of the assemblies was controlled using the assembly statistics
calculated by the use of the tool QUAST (v5.0.2) (58). High-quality assemblies were annotated using
Prokka (v1.12) software (default parameters, contigs  500 bp) to identify open reading frames (59).
Publicly available E. coli reference genomes (see Text S1 in the supplemental material) were downloaded
from NCBI and annotated as described above. In silico multilocus sequence typing (MLST) was performed
using the mlst (v2.11) program (60) (default parameters). Sequenced and acquired isolates were analyzed
using a variety of computational programs (Text S1).
Urine DNA extraction and 16S rRNA sequencing and analysis. Total DNA was extracted from 2 ml
of previously frozen urine samples using the QIAamp bacteremia DNA kit (Qiagen, Germantown, MD,
USA). Amplicon libraries of the variable region (V4) of the 16S rRNA gene were constructed using the
515F/806R PCR primers, including Illumina adapter sequences, and the Earth Microbiome protocols (61).
Twenty-five-microliter reaction mixtures consisting of 10 l H2O, 12.5 l Taq Hot-Start DNA polymerase
(TaKaRa, Kusatsu, Japan), 1 l forward primer (10 M), 1 l reverse primer (10 M), and 0.5 l template
DNA (1 ng/l) were prepared in 96-well plates. PCRs were performed in triplicate (settings, 98°C for 30
s; 98°C for 10 s, 50°C for 30 s, and 72°C for 30 s for 35 cycles; 72°C for 2 min). A template-less
negative-control reaction was carried out for each reaction. PCR product purity was assessed via gel
electrophoresis. 16S rRNA gene amplicons were sequenced on an Illumina MiSeq platform (2  250 bp).
Demultiplexed raw reads were quality filtered and cleaned from chimeric reads, and the feature table was
generated using the dada2 denoise-paired option in the Qiime 2 plug-in (62). The feature table was
rarefied to a sampling depth of 5,000 reads. Taxonomy was assigned using the SILVA rRNA database (63).
To detect microbiota signatures associated with a predisposition for rUTIs, the bacterial compositions in
rUTI and non-rUTI patients with insignificant uropathogen colonization were analyzed. For this purpose,
an insignificant uropathogen burden was defined as a 0.25% relative uropathogen abundance, as
determined by 16S rRNA gene sequencing, and the detection of less than 10,000 CFU by semiquanti-
tative culturing. Additionally, samples collected immediately preceding a recurrence were analyzed to
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detect the microbiota signatures preceding the recurrence. Therefore, rUTI patients were matched to
non-rUTI patients based on the identified uropathogen, and time-matched samples were analyzed.
Results were analyzed and visualized in R using the vegan and ggplot2 packages.
Antibiotic susceptibility testing. Antimicrobial susceptibility testing was performed on Mueller-
Hinton agar (Hardy Diagnostics, Santa Maria, CA, USA) using the Kirby-Bauer disk diffusion method.
Antibiotic disks were purchased from Hardy Diagnostics (Santa Maria, CA, USA) and Becton, Dickinson
(Franklin Lakes, NJ, USA). Results were interpreted according to CLSI guidelines (64).
Data availability. The data sets generated and analyzed during this study are deposited in the NCBI
Sequence Read Archive under BioProject accession no. PRJNA530794.
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